Principal Financial Group Inc Fate Therapeutics Inc Transaction History

Principal Financial Group Inc

  • $160 Billion
  • Q2 2024

A detailed history of Principal Financial Group Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Principal Financial Group Inc holds 13,668 shares of FATE stock, worth $48,794. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,668
Previous 23,876 42.75%
Holding current value
$48,794
Previous $175,000 74.86%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024
SELL
$3.26 - $7.08 $33,278 - $72,272
-10,208 Reduced 42.75%
13,668 $44,000
Q1 2024

Apr 29, 2024
SELL
$3.54 - $8.35 $10,304 - $24,306
-2,911 Reduced 10.87%
23,876 $175,000
Q4 2023

Feb 07, 2024
SELL
$1.65 - $3.94 $2,879 - $6,875
-1,745 Reduced 6.12%
26,787 $100,000
Q3 2023

Nov 02, 2023
BUY
$2.02 - $5.04 $5,851 - $14,600
2,897 Added 11.3%
28,532 $60,000
Q2 2023

Aug 07, 2023
BUY
$4.76 - $6.59 $12,780 - $17,694
2,685 Added 11.7%
25,635 $122,000
Q1 2023

May 09, 2023
SELL
$4.24 - $11.12 $7,275 - $19,081
-1,716 Reduced 6.96%
22,950 $130,000
Q4 2022

Feb 09, 2023
BUY
$9.86 - $23.83 $13,961 - $33,743
1,416 Added 6.09%
24,666 $248,000
Q3 2022

Nov 09, 2022
SELL
$21.04 - $36.06 $9,783 - $16,767
-465 Reduced 1.96%
23,250 $521,000
Q2 2022

Aug 10, 2022
SELL
$17.78 - $42.39 $36,502 - $87,026
-2,053 Reduced 7.97%
23,715 $588,000
Q1 2022

May 09, 2022
SELL
$29.67 - $60.28 $1.3 Million - $2.65 Million
-43,891 Reduced 63.01%
25,768 $999,000
Q4 2021

Feb 09, 2022
SELL
$47.84 - $64.34 $507,343 - $682,325
-10,605 Reduced 13.21%
69,659 $4.08 Million
Q3 2021

Nov 09, 2021
SELL
$59.27 - $95.73 $5.08 Million - $8.2 Million
-85,670 Reduced 51.63%
80,264 $4.76 Million
Q2 2021

Aug 10, 2021
SELL
$67.25 - $92.52 $3.2 Million - $4.41 Million
-47,652 Reduced 22.31%
165,934 $14.4 Million
Q1 2021

May 10, 2021
BUY
$72.16 - $117.4 $12.8 Million - $20.8 Million
177,510 Added 492.04%
213,586 $17.6 Million
Q4 2020

Feb 08, 2021
BUY
$38.09 - $100.95 $351,456 - $931,465
9,227 Added 34.37%
36,076 $3.28 Million
Q3 2020

Nov 06, 2020
BUY
$30.41 - $40.5 $2,098 - $2,794
69 Added 0.26%
26,849 $1.07 Million
Q2 2020

Aug 05, 2020
BUY
$20.21 - $35.23 $339,851 - $592,427
16,816 Added 168.77%
26,780 $919,000
Q1 2020

May 12, 2020
BUY
$17.28 - $31.88 $172,177 - $317,652
9,964 New
9,964 $221,000
Q4 2019

Feb 05, 2020
SELL
$13.39 - $20.73 $136,912 - $211,964
-10,225 Closed
0 $0
Q3 2019

Nov 13, 2019
BUY
$15.47 - $22.5 $4,826 - $7,020
312 Added 3.15%
10,225 $159,000
Q2 2019

Aug 12, 2019
BUY
$15.61 - $20.44 $154,741 - $202,621
9,913 New
9,913 $201,000

Others Institutions Holding FATE

# of Institutions
190
Shares Held
123M
Call Options Held
15K
Put Options Held
14K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $346M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email